Blood-Borne Biomarkers of Mortality Risk: Systematic Review of Cohort Studies by Barron E et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Barron E, Lara J, White M, Mathers JC. Blood-Borne Biomarkers of Mortality 
Risk: Systematic Review of Cohort Studies. PLoS ONE 2015, 10(6), e0127550 
 
 
Copyright: 
© 2015 Barron et al. This is an open access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original author and source are credited. 
DOI link to article: 
http://dx.doi.org/10.1371/journal.pone.0127550  
Date deposited:   
04/08/2015 
  
RESEARCH ARTICLE
Blood-Borne Biomarkers of Mortality Risk:
Systematic Review of Cohort Studies
Evelyn Barron1*, Jose Lara1, Martin White1,2,3, John C. Mathers1
1 Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, Biomedical
Research Building, Campus for Ageing & Vitality, Newcastle upon Tyne NE4 5PL, United Kingdom,
2 Institute of Health and Society, Newcastle University, Baddiley-Clark Building, Faculty of Medical
Sciences, Newcastle upon Tyne, NE2 4AX, United Kingdom, 3 Fuse, UKCRCCentre for Translational
Research in Public Health, Institute of Health & Society, Baddiley-Clark Building, Faculty of Medical
Sciences, Newcastle upon Tyne, NE2 4AX, United Kingdom
* evelyn.barron@newcastle.ac.uk
Abstract
Background
Lifespan and the proportion of older people in the population are increasing, with far reach-
ing consequences for the social, political and economic landscape. Unless accompanied by
an increase in health span, increases in age-related diseases will increase the burden on
health care resources. Intervention studies to enhance healthy ageing need appropriate
outcome measures, such as blood-borne biomarkers, which are easily obtainable, cost-ef-
fective, and widely accepted. To date there have been no systematic reviews of blood-
borne biomarkers of mortality.
Aim
To conduct a systematic review to identify available blood-borne biomarkers of mortality
that can be used to predict healthy ageing post-retirement.
Methods
Four databases (Medline, Embase, Scopus, Web of Science) were searched. We included
prospective cohort studies with a minimum of two years follow up and data available for par-
ticipants with a mean age of 50 to 75 years at baseline.
Results
From a total of 11,555 studies identified in initial searches, 23 fulfilled the inclusion criteria.
Fifty-one blood borne biomarkers potentially predictive of mortality risk were identified. In
total, 20 biomarkers were associated with mortality risk. Meta-analyses of mortality risk
showed significant associations with C-reactive protein (Hazard ratios for all-cause mortality
1.42, p<0.001; Cancer-mortality 1.62, p<0.009; CVD-mortality 1.31, p = 0.033), N Terminal-
pro brain natriuretic peptide (Hazard ratios for all-cause mortality 1.43, p<0.001; CHD-mor-
tality 1.58, p<0.001; CVD-mortality 1.67, p<0.001) and white blood cell count (Hazard ratios
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for all-cause mortality 1.36, p = 0.001). There was also evidence that brain natriuretic
peptide, cholesterol fractions, erythrocyte sedimentation rate, fibrinogen, granulocytes,
homocysteine, intercellular adhesion molecule-1, neutrophils, osteoprotegerin, procollagen
type III aminoterminal peptide, serum uric acid, soluble urokinase plasminogen activator re-
ceptor, tissue inhibitor of metalloproteinases 1 and tumour necrosis factor receptor II may
predict mortality risk. There was equivocal evidence for the utility of 14 biomarkers and no
association with mortality risk for CD40 ligand, cortisol, dehydroepiandrosterone, ferritin,
haemoglobin, interleukin-12, monocyte chemoattractant protein 1, matrix metalloproteinase
9, myelopereoxidase, P-selectin, receptor activator of nuclear factor KappaB ligand, sex
hormone binding globulin, testosterone, transferrin, and thyroid stimulating hormone
and thyroxine.
Conclusions
Twenty biomarkers should be prioritised as potential predictors of mortality in future studies.
More studies using standardised protocols and reporting methods, and which focus on mor-
tality rather than risk of disease or health status as an outcome, are needed.
Introduction
Population demographics are changing worldwide, as people are living longer and the birth-
rate is falling in many countries. In the UK the number of adults over 60 years of age is ex-
pected to increase by 7 million over the next 20 years [1]. The proportion of the oldest old is
also growing with a predicted sevenfold increase in the number of centenarians by the middle
of this century [2]. This increase in lifespan has been attributed to a combination of factors, in-
cluding higher standards of living, education, prosperity, improved healthcare and healthier
lifestyles [3]. However, increased lifespan does not necessarily equate to increased years of
good health and can often mean a longer period of morbidity before death [4]. Longer lives
and increased age-related frailty, disability and disease will have far reaching consequences for
the social, political and economic landscape. Unless increased lifespan is accompanied by in-
creased health span, the greater burden of age-related disease will put pressure on health care
resources [4, 5] and require changes in the way these resources are distributed [6].
Research is beginning to focus on interventions to help health span to keep pace with life-
span. Most interventions focus on lifestyle factors including physical activity and diet (e.g. [7]
as means to slow functional decline, improve mood, general health (e.g. [8], cognitive perfor-
mance [9, 10] and lower mortality rates [11]. However, to assess the impact of such interven-
tions, outcome measures are needed which are suitable for use in large community based
studies and which are cost-effective, easily obtainable, and sufficiently sensitive to detect
change in response to interventions [12].
Biomarkers are objective measures that may be useful for assessing the utility of such inter-
ventions. Biomarkers of ageing should be better predictors of functional change than chrono-
logical age alone [13]. In addition Johnson has proposed that a biomarker of ageing must
monitor a process of ageing, not an underlying disease process; be usable repeatedly without
causing harm; and work equally well in animal models so that they can be validated before
being used in humans [14]. Blood-borne biomarkers fulfil these criteria [15] and are potentially
appropriate outcome measures for intervention studies. Despite decades of research, there are
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few reliable markers of ageing processes and questions remain over the reliability and validity
of such biomarkers [16, 17]. It is difficult to assess the concurrent validity of biomarkers be-
cause there is no gold-standard measure of healthy ageing [18], so for this reason we chose
mortality as the outcome in this analysis.
The aim of this systematic review was to identify blood-borne biomarkers predictive of mor-
tality which could potentially be used to assess the utility of interventions designed to improve
health span. Evidence from studies of physical activity and diet strongly suggest that the retire-
ment transition is an ideal target for lifestyle based interventions to promote healthy ageing
(e.g. [19, 20]. Therefore, this systematic review focused on studies with participants in the re-
tirement transition age window, during which interventions to promote health and wellbeing
in later life could be delivered.
Methods
Protocol
The review was conducted according to established methods (Cochrane, CRD [21]) and is re-
ported according to PRISMA guidelines [22]. The protocol was registered with the PROSPERO
database (Prospective Register of Systematic Reviews, Registration number: CRD42011001499).
Selection Criteria
Study type. Studies with a prospective cohort design and at least 2 years follow up were in-
cluded to allow the predictive value of biomarkers to be assessed. Where studies investigated
disease prevention, only primary prevention studies were included. For Medline and Embase,
standardised filters from BMJ Evidence [23] which return cohort studies were used. Equivalent
versions were not available for Web of Science and Scopus, so topic searching and index terms
respectively were used to search for cohort studies. Searches were conducted up to March 2014.
Participants. Studies that included human participants, of either sex, with blood-borne
biomarker data available for participants with a mean age of 50–75 years at baseline were in-
cluded. Studies that recruited participants based on risk factors for a disease, rather than pres-
ence of the disease itself, were included as these studies were likely to focus on primary
prevention.
Outcome measures. This review was restricted to studies examining biomarkers that are
blood-borne and where a relationship with mortality was reported. Studies that examined ge-
netic factors or biomarkers diagnostic of a particular disease rather than mortality risk were
not included in this review.
Search Strategy
Search Terms. A systematic review of the literature was conducted across Medline,
Embase, Scopus andWeb of Science. The search strategy was created in Medline and translated
for the three other databases. The specific search strategy (S1 File) included ‘biological marker’
and ‘marker’, combined with ‘blood’ and four alternative terms: ‘plasma’, ‘serum’, ‘DNA’ and
‘circulating’ and relevant synonyms. Age filters were used to increase the specificity of the
search. Reference lists of identified articles were hand searched for further relevant articles.
Publication screening, data extraction and quality assessment. Two investigators (EB
and JL) conducted title and abstract screening to identify articles justifying full text screening
according to the selection criteria. Any disagreements were resolved by discussion. The refer-
ence lists of studies accepted after full text screening were cross-checked by hand to identify
other relevant publications. Studies identified from reference cross-checking were subjected to
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the same process. Data were extracted from the full text article of all studies accepted after full
text screening using a customised data extraction form (S2 File). The data extraction form was
developed based on the York CRD guidelines [21] and the STROBE (Strengthening the Report-
ing of Observational Studies in Epidemiology) tool [24]. The form was piloted on a sample of
studies to be included in the review. Quality was assessed using the Newcastle-Ottawa Scale
[25].
Statistical data analysis
Comprehensive meta-analysis (Version 2, Biostat, Englewood NJ) and Stata (Stata/SE 11.2 for
Windows; StataCorp LP, College Station, Texas, USA) were used to pool and to meta-analyse
results from the individual studies. Pooled results were extracted and analysed as Hazard Ratios
(HR) with 95% confidence intervals. Hazard ratios for biomarkers were analysed by subgroup,
where possible. Overall Hazard ratios are also presented. A random-effects model was used
and 2-sided P values from an inverse variance statistical method are reported.
Statistical heterogeneity was evaluated using the I2 statistic [26, 27], which assesses the ap-
propriateness of pooling individual study results and the 95% CI for I2 were calculated using
Higgins et al’s method [28, 29]. Where I2 was>50%, the degree of heterogeneity was consid-
ered substantial. Potential publication bias was appraised by visual inspection of the funnel
plot of effect size against the SE for each study, with asymmetry formally assessed with Egger’s
regression test.
Results
Search Results
Fig 1 summarises the number of papers at each stage of the search. The initial search returned
11,555 papers for possible inclusion in the review. After title and abstract screening, 8,703 pa-
pers did not meet selection criteria. One hundred and twenty one studies were screened as full-
text, and 21 studies meeting our inclusion criteria were included in this review. After screening
the references of these studies, two more publications meeting our inclusion criteria were iden-
tified [30–52]. All studies were of a similar quality according to the NOS [25].
Study characteristics. The characteristics of the participants in the cohorts included in the
review varied widely, as did sample size (range: 254 to 160,309 participants), length of follow
up (range: 2.7 to 19 years) and gender balance (see Table 1). The majority of studies were from
Europe (11) with nine studies from the USA, two studies from Japan and one from Korea.
Table 1 summarises the biomarkers examined and the mortality measure reported in each
study. Fifty-one potential biomarkers of mortality were identified in this review: 25 hydroxyvi-
tamin D, albumin, alpha 1-acid glycoprotein, brain natriuretic peptide, CD40 ligand, C-reac-
tive protein, cortisol, creatinine, cystatin C, dehydroepiandrosterone sulphate, erythrocyte
sedimentation rate, ferritin, fibrinogen, granulocytes, haemoglobin, high density lipoprotein
cholesterol, homocysteine, intercellular adhesion molecule-1, interleukin 1β, interleukin 4 solu-
ble receptor, interleukin-6, interleukin 8, interleukin 10, interleukin 12, lipoprotein associated
phospholipase A2, low density lipoprotein cholesterol, lymphocytes, matrix metalloproteinase
9, myeloperoxidase, monocyte chemoattractant protein 1, monocytes, neutrophils, non-high
density lipoprotein cholesterol, N-terminal pro-brain natriuretic peptide, osteoprotegerin,
P-selectin, procollagen type III aminoterminal peptide, receptor activator of nuclear factor-
kappaB ligand, serum uric acid, sex hormone binding globulin, soluble urokinase plasminogen
activator receptor, T4, testosterone, thyroid stimulating hormone, tissue inhibitors of metallo-
proteinases 1, total cholesterol, transferrin, transthyretin, tumour necrosis factor alpha, tumour
necrosis factor receptor II and white blood cell count. It was not possible to divide all of the
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analyses by sex as some of the original studies did not provide data for males and females
separately.
Meta-analyses
C-reactive protein (CRP). C-reactive protein was examined in 12 studies [30, 33–36, 42–
44, 47, 49–51]. Meta-analysis was conducted on the relationship between CRP and mortality
and Fig 2 presents results by type of mortality. Higher CRP at baseline was significantly associ-
ated with an increased risk of all-cause mortality (HR 1.42, 1.25–1.62, p<0.0001; I2 = 64.38; Q
28.1; DF 10; p = 0.002) and cardiovascular disease (CVD) mortality (HR 1.31, 1.02–1.68,
p = 0.033; I2 = 80.44; Q 10.22; DF 2; p = 0.006), but baseline CRP has no relationship with risk
Fig 1. PRISMA diagram. Prisma diagram showing the number of references identified in the search and the number of inclusions and exclusions at
each stage.
doi:10.1371/journal.pone.0127550.g001
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of coronary heart disease (CHD) mortality (HR 1.20, 0.93–1.56, p = 0.162; I2 = 71.02; Q 6.9; DF
2; p = 0.032). Regarding other specific causes of mortality, higher CRP concentrations at base-
line were associated with greater risk of cancer mortality (HR 1.62, 1.13–2.33, p = 0.009). A
funnel plot of all meta-analysed studies on CRP did not show asymmetry and Egger’s regres-
sion test was not significant (p = 0.44) indicating likely absence of publication bias.
Subgroup analysis by follow-up length showed that among studies with follow up of 5 years
or less (HR, 1.57, 1.14–2.17, p = 0.006; I2 = 66.81; Q 6.02; DF 2; p = 0.049) and studies with fol-
low-ups over 5 years (HR 1.40, 1.17–1.67, p<0.0001; I2 = 67.92; Q 21.81; DF 7; p = 0.003) the
association between CRP and all-cause mortality remained significant. Comparison of these
subgroups showed no significant differences (p = 0.540).
N-Terminal pro Brain Natriuretic Peptide (NT-proBNP). Overall, higher concentra-
tions of NT-proBNP at baseline were associated with greater subsequent mortality (Fig 3). Kis-
torp et al [34] and McKie et al [37] examined relationships between NT-proBNP and all-cause
mortality risk while Wannamethee et al [49] andWelsh et al [50] examined links with CVD
and CHDmortality. Higher concentrations of NT-proBNP were associated with greater risk of
all-cause mortality (HR 1.43, 1.18–1.74, p<0.0001; I2 = 0; Q 0.001; DF 1; p = 0.97), CHDmor-
tality (HR 1.58, 1.30–1.91, p<0.0001; I2 = 71; Q 6.93; DF 2; P = 0.031) and CVDmortality (HR
Fig 2. Forest plot of Hazard ratios for all-cause, cancer, CHD-related, and CVD-related mortality for each 1-SD increase in CRP.
doi:10.1371/journal.pone.0127550.g002
Fig 3. Forest plot of Hazard ratios for all-cause, CHD-related, CVD-related, and Non-CVD-related
mortality for each 1-SD increase in NT proBNP.
doi:10.1371/journal.pone.0127550.g003
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1.67, 1.33–2.10, p<0.0001; I2 = 88; Q 16.88; DF 2; p = 0.0002). One study reported an associa-
tion with non-CVD mortality.
Interleukin-6 (IL-6). Baune et al [31], Baylis et al [42] and Schnabel et al [47] investigated
associations between IL-6 and mortality. Both Baune et al [31] and Schnabel et al [47] found
significant associations between increased levels of IL-6 and increased mortality risk (HR 2.47,
1.3–4.7, p = 0.006; HR 1.41, 1.28–1.55, p<0.0001 respectively). However, Baylis et al [42]
found no association (Fig 4) between IL-6 and 10 year mortality (HR 0.96, 0.77–0.91,
p = 0.713). Overall, the meta-analysis showed no relationship between IL-6 and mortality risk
(HR 1.35, 0.94–1.94, p = 0.104; I2 = 85.28 (95%CI 57 to 95); Q = 13.56, DF = 2; p = 0.0001).
White Blood Cell (WBC) count. Four studies examine the association between WBC
count and all-cause mortality [41, 42, 44, 52]. Higher WBC count at baseline was associated
with greater risk of all-cause mortality (Fig 5) (HR 1.36, 1.13–1.64, p = 0.001). I2 was significant
(I2 = 79.9, (95%CI 47 to 92) Q = 14.95, df = 3, p = 0.0001). Although the Egger test was non-sig-
nificant (p = 0.73), with only 4 studies the possibility of publication bias cannot be excluded.
Narrative review
For the remaining putative biomarkers of mortality risk, there were too few studies to warrant
meta-analysis.
Fig 4. Forest plot of Hazard ratios for all-causemortality risk for each 1-SD increase in IL-6.
doi:10.1371/journal.pone.0127550.g004
Fig 5. Forest plot of Hazard ratios for all-causemortality risk and increases in white blood cell count.
doi:10.1371/journal.pone.0127550.g005
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25 Hydroxyvitamin D (25(OH)D). Overall, there was no association between 25(OH)D
and all-cause, CV and non-CV mortality but higher 25(OH)D concentrations were protective
in men with intermediate to high coronary risk scores for all-cause (HR 0.60, 0.44–0.82,
p = 0.001) and CV mortality (HR 0.46, 0.29–0.73, p = 0.001) [51].
Brain Natriuretic Peptide (BNP). There was a significant positive association between
baseline BNP concentrations and all-cause mortality risk (HR 2.98,2.39–3.72, p<0.001) [37].
Carrier Proteins. Albumin. Carriere et al [30] examined the association between plasma
albumin concentration and all-cause mortality risk at5 and 5 to 9 years of follow up. Albu-
min concentrations in the lowest quartile were associated with higher mortality risk at 5
years follow up (HR 2.72, 1.44–5.14, p = 0.002) in males but no association was found in males
at 5 to 9 years of follow up or in females at either time point. Similarly Kabagambe et al [44] re-
ported no association between lower albumin concentrations and all-cause mortality (HR 0.81,
0.74–0.89) and Baylis et al [42] found no association in males or females at 10 years follow up
(HR 0.93, 0.77–1.11, p = 0.401).
Ferritin. Menke et al [46] found that ferritin concentrations varied widely by gender and
female menopause status. However, higher ferritin concentrations were not associated with in-
creased risk of all-cause mortality when comparing the fourth versus the second quartiles in
premenopausal women (HR 1.43, 0.63–3.23, p = 0.31), postmenopausal women (HR 1.03,
0.79–1.34, p = 0.95) or men (HR 1.09, 0.82–1.44, p = 0.92).
Haemoglobin. Baylis et al [42] reported no association between haemoglobin and all-
cause mortality risk at 10 years follow up (HR 0.98, 0.78–1.24, p = 0.894).
Transthyretin (TTR). Carriere et al examined the association between TTR and all-cause
mortality at two time points. Those participants in the lowest quartile of TTR had a greater risk
of mortality at5 years follow up (males HR 2.23, 1.21–4.13, p = 0.01; females HR 2.39, 1.24–
4.58, p = 0.009) but this apparently greater risk was not present at 5 to 9 years follow up [30].
Cell Adhesion Molecules (CAM). Intercellular Adhesion Molecule-1 (ICAM-1). Schna-
bel et al [47] examined the association between inflammatory biomarkers and mortality risk
and found a significant positive association between ICAM-1 and mortality risk (HR 1.24,
1.12–1.37, p<0.0001 per 1SD increase in ICAM-1).
P-selectin and CD40 ligand. In contrast, Schnabel et al [47] found no associations be-
tween P-selectin or CD40 ligand and mortality risk (HR 1.10, 0.99–1.23, p = 0.08 and HR 1.00,
0.90–1.12 p = 0.97 respectively).
Cholesterol fractions. Total Cholesterol (TC). Carriere et al [30] divided participants
into sex-specific quartiles of TC at baseline and, to investigate possible non-linear associations
between TC and subsequent mortality, created three groups (low quartile, middle quartiles,
high quartile), and expressed the HR of mortality relative to the middle category. For both
sexes, there were tendencies towards greater mortality in the initial 5 years of follow-up for
those in the lowest and highest TC quartiles but this effect was significant (HR 2.21, 1.06–4.62,
p = 0.03) for the lowest TC quartile in women only. With longer term follow-up (5 to 9 years),
there were no significant associations between baseline TC and subsequent mortality. Cui et al
[32] reported a positive linear relationship between baseline TC and cardiovascular mortality
with greater mortality risk in males with higher baseline TC concentration (RR 2.07, 1.39–
3.08). The association between baseline TC and cardiovascular mortality was weaker, and not
statistically significant, in females (RR 1.21, 0.68–2.16).
High Density Lipoprotein Cholesterol (HDL-C). HDL-C was negatively associated with
all-cause mortality with a significantly lower risk (p = 0.01) in those with the highest baseline
HDL-C concentrations (1.82 mmol/L; HR 0.7, 0.53–0.93). When stratified by sex, this trend
was significant in females (HR 0.63, 0.41, 0.94, p = 0.03) but not males (HR 0.73, 0.50, 1.06,
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p = 0.10) [39]. This negative association was also present for cardiovascular mortality (males
RR 0.41 (0.27–0.61; females RR 0.34 (0.20–0.57)) [32].
Low Density Lipoprotein Cholesterol (LDL-C). Risk of all-cause mortality was higher in
those males and females with the highest baseline LDL-C concentrations (4.91 mmol/L;)
compared with the lowest concentrations (<3.36 mmol/L; males RR 1.23, 0.96–1.58; females
RR 1.12, 0.84–1.49). A similar pattern was seen for cardiovascular mortality (males RR 1.77,
1.22–2.59; females RR 1.37, 0.82–2.27) [32].
Non High Density Lipoprotein Cholesterol (Non HDL-C). There was a positive associa-
tion between non HDL-C and all-cause mortality for both males (RR 1.49, 1.18–1.88) and fe-
males (RR 1.61, 1.22–2.12). Cardiovascular mortality risk was also increased with higher non
HDL-C concentrations in both sexes (males RR 2.14, 1.50–3.04; females RR 2.43, 1.47–4.00)
[32].
Comparison of cholesterol fractions. Cui et al [32] compared the ability HDL-C, non
HDL-C and LDL-C to predict CVD mortality risk based on the magnitude of the correspond-
ing RR estimate. In males HDL-C (RR 0.77, 0.69–0.86) and non HDL-C (RR 1.19, 1.13–1.26)
were similarly predictive while LDL-C was less predictive (RR 1.11, 1.02–1.22). In females
HDL-C was the strongest predictor (RR 0.77, 0.69–0.88) followed by non HDL-C (RR 1.15,
1.06–1.25) and then LDL-C (RR 1.08, 0.96–1.22).
Cystatin C (CysC). Wu et al [51] divided their participants into groups based on coronary
risk scores. In males cysC was significantly associated with all-cause and non-CV mortality in
the low risk group (HR2.31, 1.42–3.76, p = 0.001; HR 2.32, 1.28–4.19, p = 0.005 respectively),
all-cause, CV and non-CV mortality in the intermediate risk group (HR 1.44, 1.10–1.88,
p = 0.008; HR 1.60, 1.05–2.44, p = 0.029; HR 1.36, 0.96–1.94, p = 0.084 respectively) and all-
cause and CV mortality in the intermediate-to-high risk group (HR 1.22, 1.06–1.40, p = 0.006;
HR 1.36, 1.11–1.68, p = 0.004 respectively). In females, cysC was significantly associated with
all-cause and CV mortality risk in the intermediate (HR 1.34, 1.09–1.64, p = 0.005; HR 1.73,
1.28–2.33, p<0.001 respectively) and intermediate-to-high risk groups (HR 1.29, 1.08–1.54,
p = 0.006; HR 1.52, 1.17–1.98, p = 0.002 respectively).
Cytokines and cytokine receptors. In addition to IL-6, Baune et al [31] investigated a
range of cytokines including interleukin 1b (IL-1β), interleukin 4 soluble receptor (IL-4sR), in-
terleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12 (IL-12) and tumour necrosis factor
alpha (TNF-α). Baseline concentrations of IL-1β, IL-8, IL-10 and TNF-α were significantly
higher in those who died during follow up but, after adjusting for likely confounders, this effect
remained significant for IL-8 (p = 0.041) and IL-10 only (p = 0.018). However, in contrast with
IL-6, there was no dose-response relationship between tertiles of IL-8 (HR 1.35, 0.7–2.50,
p = 0.34) and IL-10 (HR 1.24, 0.7–2.1, p = 0.45 and mortality risk. Baylis et al [42] found weak
evidence that IL-1β was associated with all-cause mortality (HR 1.17, 1.00–1.36, p = 0.044)
since this relationship was significant in the unadjusted model only. Schnabel et al [47] found
no association between monocyte chemoattractant protein-1 (MCP1) and mortality.
Enzymes. There were no associations between matrix metalloproteinase 9 (MMP-9) (HR
1.24, 0.62–2.49, p = 0.54) [48] or myeloperoxidase (HR 1.02, 0.91–1.13, p = 0.78) [47] and mor-
tality risk. Whilst lipoprotein associated phospholipase A2 (Lp-PLA2) activity was associated
with mortality risk (HR 1.16, 1.01–1.32, p = 0.03) Lp-PLA2 mass was not (HR 1.07, 0.96–1.19,
p = 0.20) [47].
Erythrocyte Sedimentation Rate (ESR). Baylis et al [42] reported a significant association
between higher ESR and increased mortality risk (HR 1.33, 1.11–1.58, p = 0.002).
Glycoproteins. Alpha 1-acid glycoprotein (AAG). Carriere et al (2008) reported that
AAG concentrations in the highest quartile were associated with significantly increased mortal-
ity risk at5 years follow up (males HR 2.26, 1.19–4.31, p = 0.01; females HR 2.61, 1.27–5.35,
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p = 0.009). At 5 to 9 years follow up, compared with the middle quartiles, mortality rates for
men in the lowest quartile were reduced significantly (HR 0.38, (0.16–0.92, p = 0.03) but there
was no such effect in women [30].
Fibrinogen. Wu [51] reported a significant association between fibrinogen and all-cause
mortality (HR1.43, 1.10–1.88, p = 0.009 and cardiovascular mortality (HR1.69, 1.13–2.52,
p = 0.01) in males with intermediate cardiovascular risk. Schnabel et al [47] also found that
higher fibrinogen concentrations were associated with increased all-cause mortality risk (HR
1.15, 1.03–1.29, p = 0.02) in males and females combined.
Tissue Inhibitors of Metalloproteinases 1 (TIMP1). Higher levels of TIMP-1 were asso-
ciated with greater risk of mortality (HR 1.97, 1.53–2.53, p = 0.001) [48].
Sex Hormone Binding Globulin (SHBG). There was no evidence that SHBG levels were
associated with mortality risk (HR 0.93, 0.77–1.11, p = 0.411) [42].
Transferrin. Menke et al [46] reported that levels of transferrin saturation differed by gen-
der and menopause status. However, there was no evidence that higher levels of transferrin
were associated with increased risk of all-cause mortality when comparing the fourth versus
the second quartiles in premenopausal women (HR 1.48, 0.70–3.11, p = 0.60), postmenopausal
women (HR 1.17, 0.92–1.49, p = 0.63) or men (HR 1.08, 0.82–1.43, p = 0.62).
Homocysteine. Among American participants in the Third National Health and Nutrition
Examination Survey (NHANES III), higher plasma homocysteine concentrations were associ-
ated with increasing CV mortality risk (HR 1.30, 1.02–1.66, p = 0.032) [51].
Hormones. Baylis et al [42] found no associations between mortality risk and concentra-
tions of cortisol (HR 1.08, 0.90–1.31, p = 0.409), testosterone (in males only; HR1.18, 0.98–
1.42, p = 0.075), thyroid stimulating hormone (TSH) (HR 0.94, 0.78–1.13, p = 0.521) or thyrox-
ine (T4) (HR 0.95, 0.79–1.14, p = 0.609).
Inflammation-related Receptors. Osteoprotegerin (OPG) and Receptor Activator of Nu-
clear Factor KappaB ligand (RANKL). Among 3250 Framingham Study participants (54%
of whom were women), there was a positive association between OPG and all-cause mortality
(HR 1.31, 1.14–1.50, p = 0.0002) [45]. However Lieb et al [45] found no association between
RANKL and mortality risk (HR 0.89, 0.78–1.01, p = 0.07) in the same study.
Soluble Urokinase Plasminogen Activator Receptor (suPAR). Higher baseline concen-
trations of suPAR were associated with increased risk of mortality at 13 years of follow up.
Males in the lowest suPAR quartile at baseline survived on average 8.4 years longer than those
in the highest quartile (p<.0001) while females in the lowest quartile survived an average of
4.7 years longer (p<.0001) [33].
Tumour Necrosis Factor Receptor II (TNFRII). In a community-based study of 3035
participants, Schnabel et al [47] reported a significant association between TNFRII and mortal-
ity risk (HR 1.33, 1.19–1.49, p =<0.0001).
Metabolites. Creatinine. Serum creatinine was predictive of CV mortality only in inter-
mediate and high coronary risk groups among NHANES III participants [51].
Dehydroepiandrosterone Sulphate (DHEAS). In community-dwelling older people,
there was no association between DHEAS and all-cause mortality (HR 1.18, 0.97–1.43,
p = 0.091), although lower levels of DHEAS were associated with increased risk of frailty at ten
years follow up [42].
Serum Uric Acid (SUA). Three studies investigated the relationship between SUA and
mortality and found similar effects [38, 40, 51]. Using data from 1423 middle-aged Finnish
men, Niskanen et al [38] reported an increase in all-cause mortality risk between the lowest
(3.03–5.08 mg/dL) and highest (5.89–9.58 mg/dL) tertiles of baseline SUA concentrations (RR
1.82–1.12–2.97, p = 0.02) and cardiovascular mortality risk was greater in those with the high-
est SUA concentrations (RR 3.73, 1.42–9.83, p = 0.01). Wu et al [51] also reported a significant
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association between SUA and all-cause mortality in male participants in NHANES III with low
CV risk (HR 1.15, 1.04–1.27, p = 0.007). In a large cohort of 28,613 Austrian women, Strasak
et al [40] reported greater risk of cardiovascular mortality in those in the highest versus the
lowest quartiles of SUA (HR 1.52, 1.37–1.70; p<0.0001).
Procollagen Type III Aminoterminal Peptide (PIIINP)
For 922 Framingham Study participants, each SD increase in log-PIIINP was associated with
almost 50% increased mortality risk (HR 1.48, 1.13–1.93, p = 0.004) [48].
White Blood Cell (WBC) Individual Components
Two reported associations between WBC components and mortality. Among almost 10,000
Korean elders, all-cause mortality risk increased significantly in those with the highest com-
pared with the lowest quartiles of granulocytes (HR 3.29, 1.87–5.78, p<0.001) [41]. Among
participants of the Hertfordshire Ageing Study, higher neutrophils were associated with in-
creased mortality (HR 1.33, 1.11–1.59, p = 0.002) [42]. The results for monocytes were less con-
sistent. Kim et al [41] reported higher mortality risk for those in the highest versus the lowest
quartiles of monocytes (HR 9.93, 4.78–20.65, p<0.001) whereas Baylis et al [42] found no sig-
nificant association (HR1.19, 1.00–1.43, p = 0.054). The evidence for links between lymphocyte
count and mortality was weak. Baylis et al [42] found no association with mortality risk (HR
1.10, 0.91–1.32, p = 0.319) while Kim et al [41] reported a significant association (HR 0.68,
0.42–1.08, p = 0.006) which was lost in the adjusted models.
Discussion
Summary of principal findings
This systematic review identified 51 blood-borne biomarkers for which relationships between
baseline values and subsequent mortality risk were assessed in individuals initially aged 50–
75years. The biological role of each of these biomarkers is described briefly in Table 2. Of these
51 potential biomarkers, there was evidence of significant associations with mortality risk for
20 biomarkers. The strongest evidence available was for those biomarkers for which there were
sufficient studies to allow meta-analyses. These meta-analyses confirmed that higher baseline
concentrations of CRP, NT-proBNP and WBC count were associated with greater mortality
risk. There was also more limited evidence that BNP, cholesterol fractions (TC, non HDL-C,
HDL-C & LDL-C), ESR, fibrinogen, granulocytes, homocysteine, ICAM-1, neutrophils, OPG,
PIIINP, SUA, SUPAR, TIMP1 and TNFRII also predicted mortality. Relationships with mor-
tality for AAG, albumin, creatinine, cysC, IL-1β, IL-4sR, IL-8, IL-10, LpPLA2, lymphocytes,
monocytes, OH(25)D, TNFα and TTR were less consistent and did not remain stable between
studies, over time of follow up, between participant groups or after adjusting for confounders.
There was no evidence of significant associations between baseline CD40, cortisol, DHEAS, fer-
ritin, haemoglobin, IL-12, MCP1, MMP-9, myelopereoxidase, P-selectin, RANKL, SHBG, T4,
testosterone, transferrin, and TSH and mortality risk.
Strengths and limitations
This systematic review is the first to examine the potential utility in predicting mortality risk of
blood-borne biomarkers. Whilst a relatively large number of putative risk biomarkers were
identified, in most cases there were only a few studies reporting on a given biomarker and these
studies differed considerably in terms of participant numbers and characteristics. This limited
our ability to undertake meta-analyses and sub-group analyses so caution should be used when
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interpreting findings from those biomarkers considered in the narrative review. Furthermore,
as a sensitivity analysis for CRP where we had the most studies, the meta-analysis was re-run
after excluding the data fromMakita et al [36], which had the largest sample size. The results
remained consistent with the outcomes from original meta-analysis (S1 Fig). The review was
constrained by available data, particularly the heterogeneity of mortality in different study pop-
ulations. In addition the categorisation of high and low levels of a given biomarker was deter-
mined by the criteria used by the authors of each as individual level data were not used in this
review. A strength of the current analysis is that it focussed on studies which used prospective
cohort designs and this identified studies which had relatively large sample sizes and relatively
long durations of follow up. A weakness of the evidence included in this review is that that the
biomarkers were measured only once at baseline, and therefore there is no information on risk
of misclassification and no data about changes in the biomarker over the follow up period. Al-
though the included studies were performed in several locations in Europe, the USA, Japan and
Korea, it was not possible to determine whether there were systematic differences in the predic-
tive utility of specific biomarkers among different ethnic groups or according to geography.
Relationship to previous studies
All of the blood-borne biomarkers identified in this review fulfil some of Johnson’s [14] criteria
for biomarkers of ageing because they can be tested repeatedly without harm to the person
and, at least in principle, would work equally well in animal models. Some, e.g. those that assess
inflammation or metabolic stress, may monitor processes that underlie ageing. However, fur-
ther work is needed to confirm that these blood-borne biomarkers are a better measure of age-
ing than chronological age. Since some of the biomarkers (e.g. blood lipids concentrations) are
well-established biomarkers of cardiovascular disease risk, it is unlikely that many, if any, of
the biomarkers reported in the present study will fulfil the criterion of measuring only ageing
processes and not disease processes. In this respect, it is likely to prove difficult to separate bio-
markers of ageing from those which predict risk of age-related disease.
Interpretation and importance of the findings
The main finding of this systematic review was the identification of 20 blood-borne biomarkers
that predict mortality risk in middle-aged people. Of these 20, there were sufficient, similar
studies reporting on well-established biomarkers such as CRP, NT-proBNP and WBC count to
permit meta-analysis which confirmed the potential predictive value of these biomarkers.
More evidence is necessary to establish the value of novel biomarkers and whether these add
further predictive value to more established ones. One possible use of the biomarkers identified
here is as outcome measures in future intervention studies aimed at enhancing healthy ageing.
However, it cannot be assumed that blood-borne biomarkers which predict (or are associated
with) risk of mortality will be suitable as outcome measures for such intervention studies be-
cause healthy ageing has yet to be defined adequately and, as a consequence, surrogate end-
points such as mortality may be inappropriate [12]. In addition, blood-borne biomarkers
measured in middle age which are predictive of later health may not be reliable when used with
other age groups (e.g. [56]).
Implications for further research
The blood-borne biomarkers identified in this analysis need to be fully evaluated for their pre-
dictive capability and responsiveness to lifestyle-based interventions before they can be recom-
mended to assess the utility of such interventions. In addition, it will be important to know i)
whether there is redundancy within the 20 biomarkers identified here and ii) which of the
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biomarkers are the most predictive. Given that ageing is a complex process affecting all body
systems, it is possible that a panel of biomarkers (a subset of the 20 identified by this review)
would be better than any of the biomarkers individually; this hypothesis also needs to be tested.
It may be possible to compare the utility of a range of biomarkers using data from different
study designs using the horizontal systematic review method (e.g. [57]). Expansion of the age
range for participants included in the review would be useful to determine whether the most
predictive biomarker panels change with age.
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